

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported):
December 18, 2023

CHEMED CORPORATION

(Exact name of registrant as specified in its charter)

Delaware
(State or other
jurisdiction of
incorporation)

1-8351
(Commission File Number)

31-0791746
(I.R.S. Employer
Identification
Number)

2600 First Financial Center, 255 East 5th Street, Cincinnati, OH 45202
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code:
(513) 762-6690

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240-14a-12)
 Pre-commencement communications pursuant to Rule 14d-2(b) under Exchange Act (17 CFR 240-14d-2(b))
 Pre-commencement communications pursuant to Rule 13e-4 (c) under Exchange Act (17 CFR 240-13e-4(c))

Securities registered pursuant to 12(b) of the Act:

Title of each class	Trading symbol	Name of each exchange on which registered
Capital stock \$1 par value	CHE	NYSE

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.02 (c) Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers, Compensatory Arrangements of Certain Officers.

On December 18th, the Company's Board of Directors appointed Michael Witzeman as the Company's Chief Financial Officer, effective as of January 1, 2024. Mr. Witzeman will continue in his roles as the Controller and a Vice President of the Company.

Mr. Witzeman has been a Named Executive Officer since 2020 and will continue to participate in the benefit and other plans and arrangements he currently participates in, as described most recently in our 2023 Proxy Statement for the Annual Meeting of Stockholders dated May 15, 2023.

Item 9.01 Financial Statements and Exhibits

d) Exhibit

99.1 [Press Release dated December 18, 2023](#)

104 The cover page from this Current Report on Form 8-K formatted in Incline XBRL

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: December 18, 2023

CHEMED CORPORATION

By: /s/ Brian C. Judkins
Brian C. Judkins
Chief Legal Officer



CONTACT: Michael D. Witzeman
(513) 762-6714

Chemed Corporation Announces the Appointment of Michael D. Witzeman as CFO

CINCINNATI, December 18, 2023--Chemed Corporation (NYSE: CHE) – Today Chemed Corporation’s Board of Directors has appointed Michael D. Witzeman as Chief Financial Officer, effective January 1, 2024, following the retirement of David P. Williams from that role.

Mr. Witzeman is currently Chemed’s Vice President and Controller and serves as Chemed’s principal accounting officer. He joined Chemed in 2005 following employment as Senior Manager of Assurance at Deloitte & Touche LLP. He is a licensed CPA and a BBA in Accounting from the University of Cincinnati and an MBA from The Ohio State University.

Listed on the New York Stock Exchange and headquartered in Cincinnati, Ohio, Chemed Corporation (www.chemed.com) operates two wholly owned subsidiaries: VITAS Healthcare and Roto-Rooter. VITAS is the nation's largest provider of end-of-life hospice care and Roto-Rooter is the nation's leading provider of plumbing and drain cleaning services.

Statements in this press release or in other Chemed communications may relate to future events or Chemed's future performance. Such statements are forward-looking statements and are based on present information Chemed has related to its existing business circumstances. Investors are cautioned that such forward-looking statements are subject to inherent risk and that actual results may differ materially from such forward-looking statements. Further, investors are cautioned that Chemed does not assume any obligation to update forward-looking statements based on unanticipated events or changed expectations.

###
